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Abstract 27 
Background: Electrochemotherapy combines electroporation in conjunction with 28 
chemotherapeutic agents and is used to treat tumours in many localisations, including 29 
cutaneous metastases. The symptoms associated with cutaneous malignant wounds can be 30 
distressing for patients and their management is a challenge in healthcare. 31 
Aim: The purpose of this systematic review was to investigate the effectiveness of 32 
electrochemotherapy in the context of palliative care. 33 
Design: All aspects of the systematic review were followed according to the Preferred 34 
Reporting Items for Systematic Reviews and Meta-Analyses statement.  35 
Data Sources: The following databases were searched for English-language reviews; 36 
Medline, Embase, CINAHL, British Nursing Index and the Cochrane Library. The search 37 
was conducted between the publication of Standard Operating Procedures in 2006 and the 38 
third week of October 2017. Studies involving oral cancers and studies with fewer than 10 39 
patients were excluded. The selected studies were assessed for risk of bias and sub-group data 40 
were synthesised in a random-effects meta-analysis.  41 
Results: From 425 studies, 29 studies were included involving 1,503 patients, the pooled 42 
results were 46.6% for complete response and 82.2% for objective response according to the 43 
Response Evaluation Criteria in Solid Tumours. The meta-analysis indicated that small 44 
tumours were over twice as likely (2.25) to have a complete response than large. 45 
Conclusions: Electrochemotherapy is an effective, repeatable and minimally invasive 46 
intervention within the palliative population that can reduce symptom burden. This review is 47 
an update of previous systematic reviews by Mali et al [1,2] and highlights the need for 48 
tailored treatment depending on each individual case. 49 
Keywords 50 
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 63 
1.0 Introduction 64 
1.1 Background 65 
Cutaneous metastases are a result of primary cancers infiltrating the skin. Although their 66 
appearance can be the first detected sign of malignancy [3], cutaneous metastases are 67 
generally a sign of advanced disease. The primary aim of managing these lesions is palliative. 68 
Their presence can have a devastating impact on quality of life due to factors such as loss of 69 
body image, malodour, pain, bleeding and the inability to contain exudate [4]. Managing 70 
these symptoms can prove a challenge for health care providers due to a lack of evidence-71 
based interventions for managing malodour as well as difficulties in managing exudate with 72 
dressings [5]. A number of skin directed therapies have been developed to try to mitigate the 73 
burden of cutaneous metastases with some varying levels of success [6]; in particular there is 74 
mounting evidence for the use of electrochemotherapy as a palliative treatment for both 75 
primary skin cancers and cutaneous metastases [5]. 76 
Electrochemotherapy targets tumours in order to destroy or reduce their size. It consists of 77 
two stages; the first stage is the delivery of chemotherapeutic drugs, this is then followed by 78 
the application of electric pulses directly into the tumour approximately eight minutes later. 79 
This causes a temporary increase in the permeability of the plasma membrane of the tumour 80 
cells resulting in a rise in localised drug uptake [7]. Therefore, the aim of electroporation is to 81 
increase the absorption of chemotherapeutic drugs into cutaneous and subcutaneous 82 
cancerous cells, thereby increasing their concentration and thus their effectiveness.     83 
A large study led by Marty et al. [8] led to the publication of Standard Operating Procedures 84 
and this defined the benchmark for best practice in this field and led to standardised practice 85 
of electrochemotherapy internationally.  Further clinical trials with large sample sizes have 86 
established electrochemotherapy as an effective and safe treatment [9]. In 2018, the Standard 87 
Operating Procedures were updated to reflect the experiences obtained with its use in 88 
practice. The key changes noted in this update include robust recommendations regarding 89 
which treatment strategy to employ according to specific patient characteristics. For instance, 90 
in patients with less than seven tumours, smaller than 3cm in size local anaesthesia and local 91 
drug injection is suggested, whereas, in patients with more than 7 tumours, larger than 3cm in 92 
size general anaesthesia and intravenous drug administration is suggested. In addition, advice 93 
is given regarding the type of electrode to use according to the characteristics of individual 94 
tumours. The update also gives a comprehensive criteria that should be used to determine 95 
whether a patient is suitable for electrochemotherapy as well as standards for documentation 96 
and imaging, patient follow-ups and how to deal with reoccurrence [10].   97 
Advantages of electrochemotherapy, such as its ability to eliminate or reduce tumours to a 98 
manageable size, in turn minimises distressing symptoms and avoids unnecessary surgery to 99 
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excise tumours [11]. These make it a highly significant intervention in the context of 100 
palliative care.  101 
Two systematic reviews published in 2013 by Mali et al. [1-2] led to NICE (National Institute 102 
of Clinical Excellence) recognised electrochemotherapy as a palliative treatment for treating 103 
metastases in the skin from tumours of non-skin origin and melanoma [12]. A drawback of 104 
these reviews is that they included studies conducted before the publication of the Standard 105 
Operating Procedures in 2006 [8]. It is therefore worthwhile to review the evidence again 106 
since their publication, to exclusively evaluate the studies published since its implementation 107 
and minimise the heterogeneity which was present in the previous review.  108 
 109 
 110 
1.2 Objective  111 
The primary objective of this systematic review was to examine the available evidence for the 112 
use of electrochemotherapy to draw conclusions about its effectiveness with the primary 113 
objective of tumour response, and to make recommendations for its usage in the context of 114 
palliative care. A secondary objective was to examine the relationship between tumour size 115 
and response to treatment using a meta-analysis, again to update the previous reviews with 116 
the most recent evidence. 117 
 118 
2.0 Methods 119 
2.1 Protocol and registration 120 
This systematic review and meta-analysis were conducted at King’s College London (2018). 121 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement 122 
(PRISMA) was used as a guide to the reporting of all aspects of this systematic review [13]. 123 
 124 
2.2 Eligibility criteria 125 
Studies were eligible if they had been published after the publication of the Standard 126 
Operating Procedures in 2006 and reported data on tumour response after the delivery of 127 
electrochemotherapy with at least a four-week follow up. Case reports or studies involving 128 
fewer than 10 patients were unnecessary to include as there was an adequate number of 129 
studies with large sample sizes. Studies involving primarily oral cavity cancers were 130 
excluded as this was deemed a heterogeneous population. Studies were eligible for meta-131 
analysis if they had separate data for tumour response according to size and were of an 132 
acceptable homogeneity.  133 
The primary outcome was tumour response according to the RECIST (Response Evaluation 134 
Criteria In Solid Tumours) method [14]. These criteria define a complete response (CR) as 135 
the disappearance of all target lesions, partial response (PR) as a decrease of at least 30% in 136 
the sum of the longest diameters of all target lesions and objective response (OR) as sum of 137 
CR and PR. 138 
 139 
2.3 Information Sources 140 
The following databases were searched; Medline, Embase, CINAHL, British Nursing Index 141 
and the Cochrane Library. The search was performed during the third week of October 2017. 142 
Language restriction to English was applied as translation resources were unavailable for this 143 
review. 144 
  145 
2.4 Search 146 
 147 
To inform the search strategy the PICO format (population, intervention, comparison and 148 
outcome), was used to identify the key concepts in the review question. The Comparison 149 
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facet was omitted from the PICO table because only observational studies including 150 
prospective, retrospective studies and case series were identified in the preliminary literature 151 
search. The reason for the lack of randomised trials is likely due to the ethical concerns 152 
around conducting a trial in a palliative population and the lack of clinical equipoise relating 153 
to the intervention [15] (see supplementary material 1 for full search strategy).  154 
 155 
 156 
2.4.1 Study selection and data extraction 157 
The study selection process was performed by one independent researcher. After removal of 158 
duplicates the title and abstracts of all remaining papers were screened against the 159 
inclusion/exclusion criteria and those deemed ineligible were removed. The full-text of the 160 
remaining papers was studied and the irrelevant studies were excluded with reasons (figure 161 
1).  162 
The data were extracted from the selected studies by one researcher and displayed in 163 
evidence tables (tables 1 and 2). These studies were then screened again against the eligibility 164 
criteria for meta-analysis and the data on tumour size and response extracted (table 3). 165 
 166 
2.4.2 Data items 167 
According to the PICO format [15]; the Population was cutaneous metastases, the 168 
Intervention was electrochemotherapy and Primary Outcome was clinical response, the 169 
Comparison facet was not included due to the lack of a comparator. 170 
The information extracted from each study was as follows; study type, included number of 171 
evaluable patients, tumour response, response evaluation time, drug route, type of tumour and 172 
response evaluation method. These headings were chosen due to their similarity to the 173 
headings used in the previous systematic review [1], so comparisons could be made. A 174 
further evidence table (table 2) extracted the available data relating to further cycles of 175 
electrochemotherapy and secondary outcomes such as survival analysis, as this information 176 
would provide context to the use of electrochemotherapy in the field of palliative care. 177 
The headings included in the evidence table for meta-analysis (table 3) were; total number of 178 
small tumours and number of those achieving complete response, number of large tumours 179 
and number achieving complete response. The criteria for small and large tumour sizes were 180 
set by the individual studies and therefore studies were only included if the definition of the 181 
groups were homogeneous between studies. 182 
    183 
2.5 Risk of bias in individual studies 184 
In the case of this review the included studies were observational, prospective or 185 
retrospective case series designs. Although randomised controlled trials (RCTs) are 186 
considered the most rigorous method for determining the effectiveness of an intervention they 187 
were not present in the literature around electrochemotherapy during scoping searches. This 188 
is likely due to a lack of clinical equipoise, as electrochemotherapy has already been 189 
established as an effective palliative treatment; [1,2] therefore it would be deemed unethical 190 
to enter patients into an RCT where one intervention is believed superior to another [16]. In 191 
addition interventions for managing key symptoms (exudate and malodour) are currently 192 
lacking [5].  193 
A tool developed to assess the methodology of observational case series studies was 194 
identified, which contains an 18-criteria checklist (see supplementary material 2 for checklist) 195 
[17]. This checklist has been validated in a systematic review of quality assessment tools [18] 196 
and was deemed the most appropriate tool to assess the quality of papers in this systematic 197 
review. 198 
 199 
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2.6 Summary Measures  200 
The overall effectiveness of electrochemotherapy was determined by pooling the primary 201 
outcome data of all individual studies to calculate an overall weighted per patient Complete 202 
Response % (CR) and Objective Response % (OR).  203 
 204 
2.7 Synthesis of results 205 
A meta-analysis was used to compare sub-groups to evaluate the differences in anti-tumour 206 
effectiveness of electrochemotherapy on tumours of different sizes. For the purposes of sub 207 
group analysis, the studies with separate data for ‘small’ and ‘large’ tumours were used with 208 
‘small’ defined as ≤3cm and ‘large’ as >3cm. The relative risk (or risk ratio) was used as the 209 
measure of the size of the effect. 210 
The random- effects model was used in the meta-analysis as electrochemotherapy is a 211 
potential treatment for a wide range of tumour histologies and therefore applies to a wide 212 
patient population [19]. The I2 statistic was used to measure the variability between studies 213 
and to interpret the impact of heterogeneity on the MA; with I2<25% showing homogeneity 214 
and I2>75% showing considerable heterogeneity [20]. The calculations used were written in 215 
the Meta package which runs in the R programme according to the user manuals and forest 216 
plots were generated (figure 2) [21].  217 
 218 
2.8 Risk of bias across studies 219 
The concept of publication bias is an underlying issue within healthcare research and should 220 
be considered as a risk in systematic reviews and meta-analysis [22]. Investigating 221 
publication bias in a meta-analysis is usually done by performing a funnel plot, however, due 222 
to limited access to meta-analysis software this was not undertaken in this review. 223 
Selective reporting of bias should be investigated by comparing the methodology of a paper 224 
with the reported outcomes to make sure there is consistency between the outcomes listed in 225 
the methods section and the results reported in the findings section [23]. Any obvious 226 
reporting failures in the studies included became obvious in the data extraction process and 227 
these studies scored less in the quality appraisal tool.   228 
 229 
3.0 Results 230 
3.1 Study Selection 231 
The database search generated 425 studies after removal of duplicates. The title and abstracts 232 
of these studies were screened against the inclusion/exclusion criteria and 390 studies 233 
excluded as irrelevant. The 41 remaining studies were selected for further evaluation, the full 234 
text was obtained, read and screened against the eligibility criteria and 29 deemed eligible to 235 
be part of the review. Studies that did not meet the eligibility criteria were excluded and the 236 
reason for exclusion is detailed in the PRISMA flow chart (figure 1). The included studies 237 
were screened again against the inclusion criteria for the meta-analysis and five selected as 238 
satisfying the criteria. 239 
 240 
 241 
3.2 Study Characteristics 242 
All studies were observational and there was a combination of both prospective and 243 
retrospective approaches. The majority of studies used the Response Evaluation Criteria in 244 
Solid Tumours method [14] to measure tumour response and the follow-up period to tumour 245 
evaluation ranged between 30 days and three months.  246 
As expected, there was a wide range of tumour types across the studies; the most common 247 
being Melanoma, Basal Cell Carcinoma (BCC) and metastatic Breast Cancer. All studies 248 
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with the exception of two [24, 25] reported the maximum number of electrochemotherapy 249 
cycles performed and the number of patients that received more than one course of 250 
electrochemotherapy. Where reported, the range of number of electrochemotherapy cycles 251 
was between two and six. Some studies reported patient outcomes such as pain and quality of 252 
life.  253 
There was a lack of information across all the studies on the way survival analysis was 254 
calculated, perhaps due to the word restriction on publications. In addition, there was 255 
inconsistency between papers on the way they reported the survival analysis. Some reported 256 
progression free survival for the whole cohort of patients whereas others only calculated it for 257 
the patients with complete response.  258 
Serious adverse events were minimal. The only serious adverse event that was considered 259 
related to the intervention was reported by Bertino et al. [9] where one patient with a large 260 
ulcerated tumour died from septic shock on the second day post-electrochemotherapy. The 261 
most common reported systemic reactions were mild, post-procedural nausea and dizziness 262 
being the most common. Pain was the second most reported adverse reaction, but this was 263 
reported as transient and although some reports of extreme pain were made immediately after 264 
the therapy, this settled to manageable pain within around 48 hours.  The incidence and 265 
description of treatment toxicity was graded according to the Common Terminology Criteria 266 
for Adverse Events (CTCAE) in the majority of studies. The most frequently reported 267 
complications were skin-related such as ulceration, erythema, and other inflammatory 268 
reactions, the most severe of these were graded 4 according to the CTCAE. However, across 269 
the studies all of these were transient and did not result in permanent damage. A number of 270 
studies asked patients whether they would agree to further electrochemotherapy treatment 271 
after the initial session and the percentage of patients that answered favourably was high. For 272 
instance, in Cabula et al. [24] 97% of 96 patients answered that they would agree to receive 273 
the treatment and in Matthiessen et al. [26] 90% of 51 patients were in favour of re-treatment. 274 
 275 
  276 
3.3 Quality Appraisal and risk of bias across studies  277 
The 18-criteria checklist was used to assess the quality of included studies [17]. A study 278 
scored a point when it fulfilled a criterion with the scores displayed in table 4. Overall, 17 279 
studies of the 21 assessed received a score of 14 or more and were deemed of satisfactory 280 
quality. 281 
The researchers in this field have tried to overcome the weaknesses in their methodology by 282 
reporting the baseline characteristics of their patient populations in order to be transparent to 283 
the reader and to mitigate selection bias. This means judgements can be made about the 284 
suitability of the included patients and whether the conclusions made at the end of the study 285 
were robust. Only two of the included studies failed to report the baseline characteristics of 286 
participants, [27, 28] and these papers were awarded low scores in the quality appraisal tool. 287 
Another aspect that increased rigour was the use of standardised outcome measurement tools. 288 
In this case the majority of the papers (20 out of 29) used the Response Evaluation Criteria In 289 
Solid Tumours method [14] to measure tumour response, with the remaining using the WHO 290 
criteria [29] or stating their own measures, which in both cases were adequately similar to the 291 
Response Evaluation Criteria In Solid Tumours model. However, there was inconsistency 292 
across the studies in the timing of the tumour evaluation with a range of 30 days – three 293 
months, with three studies not reporting the time period to tumour evaluation and these 294 
papers were marked down in the quality appraisal [30-32].  295 
The majority of studies in this review were prospective (n=21) with the remaining being 296 
retrospective analyses (n=8).  It is generally the view that retrospective design is weaker in 297 
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the hierarchy of evidence than prospective design [33]. However, in this review there was not 298 
a significant difference in quality between the retrospective and prospective studies. This 299 
demonstrates that the labelling of studies does not automatically classify whether they are 300 
superior or inferior but a more thorough examination of what has been reported in the papers 301 
is required [34]. 302 
 303 
  304 
3.4 Synthesis of results 305 
The pooled data across all the studies which evaluated the tumour response per patient was 306 
46.6% for complete response and 82.2% for objective response, the total number of patients 307 
being 1194. For six studies, the data were presented as ‘per tumour’ evaluation of response 308 
and the pooled result for these data was 53.6% for CR and 71.5% for OR, the total number of 309 
tumours was 599. 310 
 311 
3.5 Meta-Analysis 312 
The five studies found eligible for meta-analysis were among the highest scoring in the 313 
quality appraisal exercise with scores ranging from 15 – 17 out of 20. Table 3 shows the data 314 
extracted. 315 
The total number of ‘small’ tumours included in the analysis was 602 and the pooled CR for 316 
this group was 67.4%. In contrast, the total number of ‘large’ tumours was 185 with a pooled 317 
complete response of 33.0%. The forest plot (figure 2) takes the ‘large’ tumour group as the 318 
control group and the ‘small’ tumour group as the experimental group. The overall relative 319 
risk in the random effects model is 2.25 95% confidence interval [1.58-3.2]. This means that 320 
‘small’ tumours ≤3cm are over twice as likely (2.25) to have a complete response than ‘large’ 321 
tumours >3cm. The test for overall effect generated a p value of <0.01 which is statistically 322 
significant, as the level of significance was set as p<0.05.  323 
The I2 statistic was 52% indicating there is moderate heterogeneity.  The p value associated 324 
with the Chi-squared test for heterogeneity is 0.08 which is statistically significant, 325 
demonstrating that the random-effects model was appropriate to use in this instance. It is 326 
important to note that the I2 in this meta-analysis will not be very precise due to the very 327 
small number of studies and the inability to detect the between study variance [19].  328 
 329 
 330 
3.6 Risk of bias across studies 331 
During the quality assessment process, the study by Di Monta et al. [37] only reported 332 
complete response data in the results section despite describing the Response Evaluation 333 
Criteria in Solid Tumours criteria and defining partial response as a primary outcome in the 334 
methods section. This meant that the objective response (the complete response + partial 335 
response) could not be calculated for this study and therefore there was an absent score for 336 
OR% when the data across all studies were pooled.  337 
When selecting studies suitable for meta-analysis it was noticed that in the study by Curatola 338 
et al. [38] the percentage response data for small tumours and large tumours was reported, 339 
but, the number of tumours in the two sub-groups was not, which meant there was not enough 340 
raw data to be included. Similarly, the results for small versus large tumours in the study by 341 
Campana et al.[39] could not be included in the meta-analysis because only the statistical test 342 
results such as odds ratio and p-value were reported and not the raw data. It was not possible 343 
to contact the authors of these studies for the raw data due to time constraints.  344 
 345 
4.0 Discussion 346 
15 
 
4.1 Summary of Evidence 347 
All the studies identified in the review reported results in favour of electrochemotherapy for 348 
the primary outcome of tumour response; it was well tolerated by patients and there were few 349 
reported serious adverse reactions.  350 
The findings of this review are consistent with the previous systematic reviews on 351 
electrochemotherapy. It is noteworthy that in this review all the studies used bleomycin 352 
exclusively as the chemotherapeutic agent except for Campana et al. [30, 40] where cisplatin 353 
was used for a small proportion of study participants. In contrast, the previous review 354 
included six studies that used cisplatin exclusively. The reason for this move towards 355 
bleomycin as the drug of choice is likely due to further evidence generated since the 356 
publication of the previous studies which showed that the uptake of bleomycin is potentiated 357 
more effectively by electroporation pulses than the uptake of cisplatin and therefore future 358 
studies began to use the bleomycin drug exclusively [41]. 359 
The meta-analysis used to perform sub-group analysis comparing the treatment response 360 
found there was a statistically significant increase of 125% in the probability of complete 361 
response for tumours ≤ 3cm compared to tumours >3cm. These findings are consistent with 362 
the previous meta-analysis [1, 2]. The reasons for this significant difference in the 363 
effectiveness of electrochemotherapy depending on tumour size has been considered in the 364 
literature [26, 42, 43] and it is believed to be multi-factorial. Firstly, in large tumours there 365 
may be insufficient exposure of the tumour to the chemotherapy drug due to inadequate blood 366 
flow across the tumour as it is harder for the drug to penetrate the centre of a larger tumour 367 
[44], therefore the drug is not adequately distributed to provide the optimum 368 
chemotherapeutic effect. Secondly, there may be insufficient coverage of the larger tumours 369 
by the electric fields simply due to the difficulty in applying the electrodes to the larger 370 
tumours, which will generally be of a less uniform size compared to the smaller tumours.  371 
Another potential explanation for why small tumours respond better to electrochemotherapy 372 
is because they have faster healing times and the fact that large tumours may be more 373 
aggressive [36]. These potential shortfalls associated with treating larger tumours could be 374 
managed with individualised treatment planning to ensure the most effective choices of type 375 
of electrode and drug administration methods are assessed in all patients prior to instigation 376 
of the therapy. This review highlights the fact that electrochemotherapy is not a one-off 377 
treatment and can be repeated.   378 
There were a number of further sub-group analyses across the studies in addition to tumour 379 
size. These include; in the study by Rotunno et al. [45] where response for 380 
electrochemotherapy performed under general versus local anaesthesia was compared and 381 
found a significant increase in CR% for patients who underwent general anaesthesia. In 382 
addition, in the study by Bertino et al. [9] the response of tumours that were treatment-naïve 383 
was compared with tumours that had been previously treated with surgical-excision or 384 
irradiation. The authors found the treatment-naïve tumours responded significantly better 385 
than the previously treated tumours. These additional analyses further enrich the breadth of 386 
knowledge about the usefulness of electrochemotherapy and provide valuable information for 387 
the review question and implications for future research. 388 
 389 
4.2 Limitations 390 
Overall, the methodological quality of the included studies was acceptable. Baseline 391 
characteristics were reported in the majority of studies, the outcome measure was fairly 392 
consistent across the included studies. However, there was inconsistency across the studies in 393 
the timing of the tumour evaluation with a range of 30 days – three months, with three studies 394 
not reporting the time period to tumour evaluation [30-32]. This makes it very difficult to 395 
form any robust conclusions about their data. It is difficult to judge how much of an effect the 396 
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difference in time to evaluation had on the reliability of the results, but it is noteworthy that 397 
the Standard Operating Procedures recommended a period of four weeks before treatment 398 
efficacy of electrochemotherapy can be determined.  399 
The survival analysis was poorly reported and inconsistent across the studies which is 400 
unfortunate as these data are of great interest to clinicians particularly when deciding whether 401 
a treatment is worthwhile in the context of palliative care. The data extracted from the studies 402 
do give an indication of the medium length of follow-up in each individual study and 403 
percentage of patients whose disease was kept at bay. It is therefore useful information to 404 
display regardless of the fact that it is not possible to obtain an overall pooled average 405 
survival statistic. 406 
Another limitation of the included studies was the use of co-interventions. These are 407 
significant as they illustrate that there are fundamental differences in the experience of a 408 
portion of patients within the studies due to adjunct treatments which may affect the tumour 409 
response data. It may also be this was more widespread than can be identified in the full-text 410 
articles if some articles did not publish the additional interventions the patients underwent in 411 
their studies. However, it can be argued that due to the disease severity of the patients in 412 
these studies it would be considered unethical to deny them the opportunity to be exposed to 413 
other tumour-targeting therapies that may assist them to alleviate the burden of living with 414 
metastatic cutaneous tumours.     415 
Overall, this systematic review includes a representative sample of the available literature on 416 
this topic area for meaningful conclusions to be made. The study selection, data extraction 417 
and study appraisal aspects of this review were carried out appropriately however, they would 418 
have been much more robust if there had been a second reviewer. Due to the availability of 419 
studies with large sample sizes, studies with less than ten participants were excluded to 420 
purposely limit the number of studies for analysis. However, the fact this occurred meant 421 
some very pertinent articles were removed that would have increased the knowledge to 422 
answer the review question [46-48]. 423 
 424 
The methods of statistical analysis were appropriate and valid in this review and an academic 425 
statistician was consulted for guidance on conducting the meta-analysis. Unfortunately, there 426 
was poor precision due to the fact there were only five studies eligible for the analysis, and it 427 
may therefore be misleading to draw firm conclusions from the summary effect.  428 
 429 
4.4 Conclusions 430 
This aim of this systematic review was to consolidate the recent literature on the effectiveness 431 
of electrochemotherapy for cutaneous metastases and update the previous systematic reviews 432 
[1, 2]. It was evident during the review process that the period of four weeks recommended 433 
by the Standard Operating Procedures as the time to measure tumour response to 434 
electrochemotherapy may not be long enough for large tumours to respond. In the study by 435 
Matthiessen et al. [26] the patients all had large tumours from breast cancer and used an eight 436 
week follow up instead of the four weeks to allow for this. Another factor noted in this 437 
review is that larger tumours may benefit from using different plates and electrodes. 438 
Additionally, a higher concentration of drug in large tumours could be achieved by 439 
combining both intratumoural and systematic administration of chemotherapy. This review 440 
used meta-analysis to show that small tumours have a greater tumour response compared to 441 
large tumours, further meta-analyses comparing other sub-groups would be useful in future 442 
reviews such as whether previous irradiation and number of tumours per patient influences 443 
the effectiveness of electrochemotherapy. Matching the treatment modality and schedule to 444 
patient specific factors such as those identified above is crucial to ensure the most effective 445 
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coverage of the tumour by the electric field which means treatment needs to become more 446 
tailored to the individual. 447 
Another implication for future treatment is that many of the studies reported some 448 
participants were able to obtain and/or maintain tumour response by undergoing repeated 449 
sessions of electrochemotherapy. Unfortunately, there was a lack of data providing the 450 
tumour responses to the additional cycles of electrochemotherapy. Further research should 451 
aim to explore this to set standards for the frequency of electrochemotherapy sessions to 452 
provide the highest benefit and lowest possible harm to patients. This could be done by better 453 
reporting of the number of cycles and results of the retreatments. Another issue this review 454 
has exposed is the lack of consistency in reporting of survival statistics as well as secondary 455 
outcomes such as QOL, pain and toxicity. Future research should address these outcomes as 456 
they inform health resource use and patient preference especially in palliative care. 457 
This systematic review shows electrochemotherapy is an effective palliative treatment with 458 
minimal adverse reactions. Moreover, it should be considered early in the development of 459 
cutaneous metastases as the smaller the tumour the more effective the treatment. Larger 460 
tumours will need to have tailored approaches to maximise the effectiveness of the ECT 461 
treatment, such as using different plates and electrodes.  462 
The evidence included in this review is based on the studies conducted following publication 463 
of the standard operating procedures in 2006 [8], it is noted that there has been an updated 464 
version of these standard operating procedures published in 2018 [10]. This update reflects 465 
the considerable experience gained in the use of the treatment in a wide range of tumour 466 
histologies. Future studies going forward, which use the updated standards may generate 467 
further clinically specific evidence to guide clinicians. The knowledge generated by this 468 
review provides evidence generated from clinical studies, which followed the 2006  Standard 469 
Operating Procedures [8,] and inform clinical practice guidelines such as the NICE guidelines 470 
[12] to ensure they are brought up-to-date with current evidence.  471 
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Abstract 27 
Background: Electrochemotherapy is a skin-directed therapy involving combines 28 
electroporationic pulses in conjunction with chemotherapeutic agents and is used to treat 29 
tumours in many localisations, including cutaneous metastases. The symptoms associated 30 
with cutaneous malignant wounds can be distressing for patients and their management is a 31 
challenge in healthcare. 32 
Aim: The purpose of this systematic review was to investigate the effectiveness of 33 
electrochemotherapy in the context of palliative care. 34 
Design: All aspects of the systematic review were followed according to the Preferred 35 
Reporting Items for Systematic Reviews and Meta-Analyses statement.  36 
Data Sources: The following databases were searched for English-language reviews; 37 
Medline, Embase, CINAHL, British Nursing Index and the Cochrane Library. The search 38 
was conducted between the publication of Standard Operating Procedures in 2006 and the 39 
third week of October 2017. Studies involving oral cancers and studies with fewer than 10 40 
patients were excluded. The selected studies were assessed for risk of bias and sub-group data 41 
were synthesised in a random-effects meta-analysis.  42 
Results: From 425 studies, 29 studies were included involving 1,503 patients, the pooled 43 
results were 46.6% for complete response and 82.2% for objective response according to the 44 
Response Evaluation Criteria in Solid Tumours. The meta-analysis indicated that small 45 
tumours were over twice as likely (2.25) to have a complete response than large. 46 
Conclusions: Electrochemotherapy is an effective, repeatable and minimally invasive 47 
intervention within the palliative population that can reduce symptom burden. This review is 48 
an update of previous systematic reviews by Mali et al [1,2] and highlights the need for 49 
tailored treatment depending on each individual case. 50 
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 64 
1.0 Introduction 65 
1.1 Background 66 
Cutaneous metastases are a result of primary cancers infiltrating the skin. Although their 67 
appearance can be the first detected sign of malignancy [3], cutaneous metastases are 68 
generally a sign of advanced disease. The primary aim of managing these lesions is palliative. 69 
Their presence can have a devastating impact on quality of life due to factors such as loss of 70 
body image, malodour, pain, bleeding and the inability to contain exudate [4]. Managing 71 
these symptoms can prove a challenge for health care providers due to a lack of evidence-72 
based interventions for managing malodour as well as difficulties in managing exudate with 73 
dressings [5]. A number of skin directed therapies have been developed to try to mitigate the 74 
burden of cutaneous metastases with some varying levels of success [6]; in particular there is 75 
mounting evidence for the use of electrochemotherapy as a palliative treatment for both 76 
primary skin cancers and cutaneous metastases [5]. 77 
Electrochemotherapy targets tumours in order to destroy or reduce their size. It consists of 78 
two stages; the first stage is the delivery of chemotherapeutic drugs, this is then followed by 79 
the application of electric pulses directly into the tumour approximately eight minutes later. 80 
This causes a temporary increase in the permeability of the plasma membrane of the tumour 81 
cells resulting in a rise in localised drug uptake [7]. Therefore, the aim of 82 
electroporationchemotherapy is to increase the absorption of chemotherapeutic drugs into 83 
cutaneous and subcutaneous cancerous cells, thereby increasing their concentration and thus 84 
their effectiveness. This occurs through the application of electric pulses directly into the 85 
tumour which causes a temporary increase in the permeability of the plasma membrane of the 86 
tumour cells resulting in a rise in localised drug uptake [7].    87 
A large study led by Marty et al. [8] led to the publication of Standard Operating Procedures 88 
and this defined the benchmark for best practice in this field and led to standardised practice 89 
of electrochemotherapy internationally. Since then, Ffurther clinical trials with large sample 90 
sizes have established electrochemotherapy as an effective and safe treatment [9]. In 2018, 91 
the Standard Operating Procedures were updated to reflect the experiences obtained with its 92 
use in practice. The key changes noted in this update include robust recommendations 93 
regarding which treatment strategy to employ according to specific patient characteristics. 94 
For instance, in patients with less than seven tumours, smaller than 3cm in size local 95 
anaesthesia and local drug injection is suggested, whereas, in patients with more than 7 96 
tumours, larger than 3cm in size general anaesthesia and intravenous drug administration is 97 
suggested. In addition, advice is given regarding the type of electrode to use according to the 98 
characteristics of individual tumours. The update also gives a comprehensive criteria that 99 
should be used to determine whether a patient is suitable for electrochemotherapy as well as 100 
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standards for documentation and imaging, patient follow-ups and how to deal with 101 
reoccurrence [10].    102 
Advantages of electrochemotherapy, such as its ability to eliminate or reduce tumours to a 103 
manageable size, in turn minimises distressing symptoms and avoids unnecessary surgery to 104 
excise tumours [1110]. These make it a highly significant intervention in the context of 105 
palliative care.  106 
Two systematic reviews published in 2013 by Mali et al. [1-2] led to NICE (National Institute 107 
of Clinical Excellence) recognised electrochemotherapy as a palliative treatment for treating 108 
metastases in the skin from tumours of non-skin origin and melanoma [1211]. A drawback of 109 
these reviews is that they included studies conducted before the publication of the Standard 110 
Operating Procedures in 2006 [8]. It is therefore worthwhile to review the evidence again 111 
since its implementation their publication, to exclusively evaluate the studies published since 112 
its implementation and minimise the heterogeneity which was present in the previous review.  113 
 114 
 115 
1.2 Objective  116 
The primary objective of this systematic review was to examine the available evidence for the 117 
use of electrochemotherapy to draw conclusions about its effectiveness with the primary 118 
objective of tumour response, and to make recommendations for its usage in the context of 119 
palliative care. A secondary objective was to examine the relationship between tumour size 120 
and response to treatment using a meta-analysis, again to update the previous reviews with 121 
the most recent evidence. 122 
 123 
2.0 Methods 124 
2.1 Protocol and registration 125 
This systematic review and meta-analysis were conducted at King’s College London (2018). 126 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement 127 
(PRISMA) was used as a guide to the reporting of all aspects of this systematic review 128 
[1312]. 129 
 130 
2.2 Eligibility criteria 131 
Studies were eligible if they had been published after the publication of the Standard 132 
Operating Procedures in 2006 and reported data on tumour response after the delivery of 133 
electrochemotherapy with at least a four-week follow up. Case reports or studies involving 134 
fewer than 10 patients were unnecessary to include as there was an adequate number of 135 
studies with large sample sizes. Studies involving primarily oral cavity cancers were 136 
excluded as this was deemed a heterogeneous population. Studies were eligible for meta-137 
analysis if they had separate data for tumour response according to size and were of an 138 
acceptable homogeneity.  139 
The primary outcome was tumour response according to the RECIST (Response Evaluation 140 
Criteria In Solid Tumours) method [1413]. These criteria define a complete response (CR) as 141 
the disappearance of all target lesions, partial response (PR) as a decrease of at least 30% in 142 
the sum of the longest diameters of all target lesions and objective response (OR) as sum of 143 
CR and PR. 144 
 145 
2.3 Information Sources 146 
The following databases were searched; Medline, Embase, CINAHL, British Nursing Index 147 
and the Cochrane Library. The search was performed during the third week of October 2017. 148 
Language restriction to English was applied as translation resources were unavailable for this 149 
review. 150 
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  151 
2.4 Search 152 
 153 
To inform the search strategy the PICO format (population, intervention, comparison and 154 
outcome), was used to identify the key concepts in the review question. The Comparison 155 
facet was omitted from the PICO table because only observational studies including 156 
prospective, retrospective studies and case series were identified in the preliminary literature 157 
search. The reason for the lack of randomised trials is likely due to the ethical concerns 158 
around conducting a trial in a palliative population and the lack of clinical equipoise relating 159 
to the intervention [15] (see supplementary material 1 for full search strategy).  160 
 161 
 162 
2.4.1 Study selection and data extraction 163 
The study selection process was performed by one independent researcher. After removal of 164 
duplicates the title and abstracts of all remaining papers were screened against the 165 
inclusion/exclusion criteria and those deemed ineligible were removed. The full-text of the 166 
remaining papers was studied and the irrelevant studies were excluded with reasons (figure 167 
1).  168 
The data were extracted from the selected studies by one researcher and displayed in 169 
evidence tables (tables 1 and 2). These studies were then screened again against the eligibility 170 
criteria for meta-analysis and the data on tumour size and response extracted (table 3). 171 
 172 
2.4.2 Data items 173 
According to the PICO format [1514]; the Population was cutaneous metastases, the 174 
Intervention was electrochemotherapy and Primary Outcome was clinical response, the 175 
Comparison facet was not included due to the lack of a comparator. 176 
The information extracted from each study was as follows; study type, included number of 177 
evaluable patients, tumour response, response evaluation time, drug route, type of tumour and 178 
response evaluation method. These headings were chosen due to their similarity to the 179 
headings used in the previous systematic review [1], so comparisons could be made. A 180 
further evidence table (table 2) extracted the available data relating to further cycles of 181 
electrochemotherapy and secondary outcomes such as survival analysis, as this information 182 
would provide context to the use of electrochemotherapy in the field of palliative care. 183 
The headings included in the evidence table for meta-analysis (table 3) were; total number of 184 
small tumours and number of those achieving complete response, number of large tumours 185 
and number achieving complete response. The criteria for small and large tumour sizes were 186 
set by the individual studies and therefore studies were only included if the definition of the 187 
groups were homogeneous between studies. 188 
    189 
2.5 Risk of bias in individual studies 190 
In the case of this review the included studies were observational, prospective or 191 
retrospective case series designs. Although randomised controlled trials (RCTs) are 192 
considered the most rigorous method for determining the effectiveness of an intervention they 193 
were not present in the literature around electrochemotherapy during scoping searches. This 194 
is likely due to a lack of clinical equipoise, as electrochemotherapy has already been 195 
established as an effective palliative treatment; [1,2] therefore it would be deemed unethical 196 
to enter patients into an RCT where one intervention is believed superior to another [1615]. 197 
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In addition interventions for managing key symptoms (exudate and malodour) are currently 198 
lacking [5].  199 
A tool developed to assess the methodology of observational case series studies was 200 
identified, which contains an 18-criteria checklist (see supplementary material 2 for checklist) 201 
[1716]. This checklist has been validated in a systematic review of quality assessment tools 202 
[1817] and was deemed the most appropriate tool to assess the quality of papers in this 203 
systematic review. 204 
 205 
2.6 Summary Measures  206 
The overall effectiveness of electrochemotherapy was determined by pooling the primary 207 
outcome data of all individual studies to calculate an overall weighted per patient Complete 208 
Response % (CR) and Objective Response % (OR).  209 
 210 
2.7 Synthesis of results 211 
A meta-analysis was used to compare sub-groups to evaluate the differences in anti-tumour 212 
effectiveness of electrochemotherapy on tumours of different sizes. For the purposes of sub 213 
group analysis, the studies with separate data for ‘small’ and ‘large’ tumours were used with 214 
‘small’ defined as ≤3cm and ‘large’ as >3cm. The relative risk (or risk ratio) was used as the 215 
measure of the size of the effect. 216 
The random- effects model was used in the meta-analysis as electrochemotherapy is a 217 
potential treatment for a wide range of tumour histologies and therefore applies to a wide 218 
patient population [1918]. The I2 statistic was used to measure the variability between studies 219 
and to interpret the impact of heterogeneity on the MA; with I2<25% showing homogeneity 220 
and I2>75% showing considerable heterogeneity [2019]. The calculations used were written 221 
in the Meta package which runs in the R programme according to the user manuals and forest 222 
plots were generated (figure 2) [2120].  223 
 224 
2.8 Risk of bias across studies 225 
The concept of publication bias is an underlying issue within healthcare research and should 226 
be considered as a risk in systematic reviews and meta-analysis [2221]. Investigating 227 
publication bias in a meta-analysis is usually done by performing a funnel plot, however, due 228 
to limited access to meta-analysis software this was not undertaken in this review. 229 
Selective reporting of bias should be investigated by comparing the methodology of a paper 230 
with the reported outcomes to make sure there is consistency between the outcomes listed in 231 
the methods section and the results reported in the findings section [2322]. Any obvious 232 
reporting failures in the studies included became obvious in the data extraction process and 233 
these studies scored less in the quality appraisal tool.   234 
 235 
3.0 Results 236 
3.1 Study Selection 237 
The database search generated 425 studies after removal of duplicates. The title and abstracts 238 
of these studies were screened against the inclusion/exclusion criteria and 390 studies 239 
excluded as irrelevant. The 41 remaining studies were selected for further evaluation, the full 240 
text was obtained, read and screened against the eligibility criteria and 29 deemed eligible to 241 
be part of the review. Studies that did not meet the eligibility criteria were excluded and the 242 
reason for exclusion is detailed in the PRISMA flow chart (figure 1). The included studies 243 
were screened again against the inclusion criteria for the meta-analysis and five selected as 244 
satisfying the criteria. 245 
 246 
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 247 
3.2 Study Characteristics 248 
All studies were observational and there was a combination of both prospective and 249 
retrospective approaches. The majority of studies used the Response Evaluation Criteria in 250 
Solid Tumours method [1413] to measure tumour response and the follow-up period to 251 
tumour evaluation ranged between 30 days and three months.  252 
As expected, there was a wide range of tumour types across the studies; the most common 253 
being Melanoma, Basal Cell Carcinoma (BCC) and metastatic Breast Cancer. All studies 254 
with the exception of two [2423, 2524] reported the maximum number of 255 
electrochemotherapy cycles performed and the number of patients that received more than 256 
one course of electrochemotherapy. Where reported, the range of number of 257 
electrochemotherapy cycles was between two and six. Some studies reported patient 258 
outcomes such as pain and quality of life.  259 
There was a lack of information across all the studies on the way survival analysis was 260 
calculated, perhaps due to the word restriction on publications. In addition, there was 261 
inconsistency between papers on the way they reported the survival analysis. Some reported 262 
progression free survival for the whole cohort of patients whereas others only calculated it for 263 
the patients with complete response.  264 
Serious adverse events were minimal. The only serious adverse event that was considered 265 
related to the intervention was reported by Bertino et al. [9] where one patient with a large 266 
ulcerated tumour died from septic shock on the second day post-electrochemotherapy. The 267 
most common reported systemic reactions were mild, post-procedural nausea and dizziness 268 
being the most common. Pain was the second most reported adverse reaction, but this was 269 
reported as transient and although some reports of extreme pain were made immediately after 270 
the therapy, this settled to manageable pain within around 48 hours.  The incidence and 271 
description of treatment toxicity was graded according to the Common Terminology Criteria 272 
for Adverse Events (CTCAE) in the majority of studies. The most frequently reported 273 
complications were skin-related such as ulceration, erythema, and other inflammatory 274 
reactions, the most severe of these were graded 4 according to the CTCAE. However, across 275 
the studies all of these were transient and did not result in permanent damage. A number of 276 
studies asked patients whether they would agree to further electrochemotherapy treatment 277 
after the initial session and the percentage of patients that answered favourably was high. For 278 
instance, in Cabula et al. [2423] 97% of 96 patients answered that they would agree to receive 279 
the treatment and in Matthiessen et al. [2625] 90% of 51 patients were in favour of re-280 
treatment. 281 
 282 
  283 
3.3 Quality Appraisal and risk of bias across studies  284 
The 18-criteria checklist was used to assess the quality of included studies [1716]. A study 285 
scored a point when it fulfilled a criterion with the scores displayed in table 4. Overall, 17 286 
studies of the 21 assessed received a score of 14 or more and were deemed of satisfactory 287 
quality. 288 
The researchers in this field have tried to overcome the weaknesses in their methodology by 289 
reporting the baseline characteristics of their patient populations in order to be transparent to 290 
the reader and to mitigate selection bias. This means judgements can be made about the 291 
suitability of the included patients and whether the conclusions made at the end of the study 292 
were robust. Only two of the included studies failed to report the baseline characteristics of 293 
participants, [2726, 2827] and these papers were awarded low scores in the quality appraisal 294 
tool. 295 
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Another aspect that increased rigour was the use of standardised outcome measurement tools. 296 
In this case the majority of the papers (20 out of 29) used the Response Evaluation Criteria In 297 
Solid Tumours method [1413] to measure tumour response, with the remaining using the 298 
WHO criteria [2928] or stating their own measures, which in both cases were adequately 299 
similar to the Response Evaluation Criteria In Solid Tumours model. However, there was 300 
inconsistency across the studies in the timing of the tumour evaluation with a range of 30 301 
days – three months, with three studies not reporting the time period to tumour evaluation and 302 
these papers were marked down in the quality appraisal [3029-3231].  303 
The majority of studies in this review were prospective (n=21) with the remaining being 304 
retrospective analyses (n=8).  It is generally the view that retrospective design is weaker in 305 
the hierarchy of evidence than prospective design [3332]. However, in this review there was 306 
not a significant difference in quality between the retrospective and prospective studies. This 307 
demonstrates that the labelling of studies does not automatically classify whether they are 308 
superior or inferior but a more thorough examination of what has been reported in the papers 309 
is required [3433]. 310 
 311 
  312 
3.4 Synthesis of results 313 
The pooled data across all the studies which evaluated the tumour response per patient was 314 
46.6% for complete response and 82.2% for objective response, the total number of patients 315 
being 1194. For six studies, the data were presented as ‘per tumour’ evaluation of response 316 
and the pooled result for these data was 53.6% for CR and 71.5% for OR, the total number of 317 
tumours was 599. 318 
 319 
3.5 Meta-Analysis 320 
The five studies found eligible for meta-analysis were among the highest scoring in the 321 
quality appraisal exercise with scores ranging from 15 – 17 out of 20. Table 3 shows the data 322 
extracted. 323 
The total number of ‘small’ tumours included in the analysis was 602 and the pooled CR for 324 
this group was 67.4%. In contrast, the total number of ‘large’ tumours was 185 with a pooled 325 
complete response of 33.0%. The forest plot (figure 2) takes the ‘large’ tumour group as the 326 
control group and the ‘small’ tumour group as the experimental group. The overall relative 327 
risk in the random effects model is 2.25 95% confidence interval [1.58-3.2]. This means that 328 
‘small’ tumours ≤3cm are over twice as likely (2.25) to have a complete response than ‘large’ 329 
tumours >3cm. The test for overall effect generated a p value of <0.01 which is statistically 330 
significant, as the level of significance was set as p<0.05.  331 
The I2 statistic was 52% indicating there is moderate heterogeneity.  The p value associated 332 
with the Chi-squared test for heterogeneity is 0.08 which is statistically significant, 333 
demonstrating that the random-effects model was appropriate to use in this instance. It is 334 
important to note that the I2 in this meta-analysis will not be very precise due to the very 335 
small number of studies and the inability to detect the between study variance [1918].  336 
 337 
 338 
3.6 Risk of bias across studies 339 
During the quality assessment process, the study by Di Monta et al. [3736] only reported 340 
complete response data in the results section despite describing the Response Evaluation 341 
Criteria in Solid Tumours criteria and defining partial response as a primary outcome in the 342 
methods section. This meant that the objective response (the complete response + partial 343 
response) could not be calculated for this study and therefore there was an absent score for 344 
OR% when the data across all studies were pooled.  345 
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When selecting studies suitable for meta-analysis it was noticed that in the study by Curatola 346 
et al. [3837] the percentage response data for small tumours and large tumours was reported, 347 
but, the number of tumours in the two sub-groups was not, which meant there was not enough 348 
raw data to be included. Similarly, the results for small versus large tumours in the study by 349 
Campana et al.[3938] could not be included in the meta-analysis because only the statistical 350 
test results such as odds ratio and p-value were reported and not the raw data. It was not 351 
possible to contact the authors of these studies for the raw data due to time constraints.  352 
 353 
4.0 Discussion 354 
4.1 Summary of Evidence 355 
All the studies identified in the review reported results in favour of electrochemotherapy for 356 
the primary outcome of tumour response; it was well tolerated by patients and there were few 357 
reported serious adverse reactions.  358 
The findings of this review are consistent with the previous systematic reviews on 359 
electrochemotherapy. It is noteworthy that in this review all the studies used bleomycin 360 
exclusively as the chemotherapeutic agent except for Campana et al. [3029, 4039] where 361 
cisplatin was used for a small proportion of study participants. In contrast, the previous 362 
review included six studies that used cisplatin exclusively. The reason for this move towards 363 
bleomycin as the drug of choice is likely due to further evidence generated since the 364 
publication of the previous studies which showed that the uptake of bleomycin is potentiated 365 
more effectively by electroporation pulses than the uptake of cisplatin and therefore future 366 
studies began to use the bleomycin drug exclusively [4140]. 367 
The meta-analysis used to perform sub-group analysis comparing the treatment response 368 
found there was a statistically significant increase of 125% in the probability of complete 369 
response for tumours ≤ 3cm compared to tumours >3cm. These findings are consistent with 370 
the previous meta-analysis [1, 2]. The reasons for this significant difference in the 371 
effectiveness of electrochemotherapy depending on tumour size has been considered in the 372 
literature [2625, 4241, 4342] and it is believed to be multi-factorial. Firstly, in large tumours 373 
there may be insufficient exposure of the tumour to the chemotherapy drug due to inadequate 374 
blood flow across the tumour as it is harder for the drug to penetrate the centre of a larger 375 
tumour [4443], therefore the drug is not adequately distributed to provide the optimum 376 
chemotherapeutic effect. Secondly, there may be insufficient coverage of the larger tumours 377 
by the electric fields simply due to the difficulty in applying the electrodes to the larger 378 
tumours, which will generally be of a less uniform size compared to the smaller tumours.  379 
Another potential explanation for why small tumours respond better to electrochemotherapy 380 
is because they have faster healing times and the fact that large tumours may be more 381 
aggressive [3635]. These potential shortfalls associated with treating larger tumours could be 382 
managed with individualised treatment planning to ensure the most effective choices of type 383 
of electrode and drug administration methods are assessed in all patients prior to instigation 384 
of the therapy. This review highlights the fact that electrochemotherapy is not a one-off 385 
treatment and can be repeated.   386 
There were a number of further sub-group analyses across the studies in addition to tumour 387 
size. These include; in the study by Rotunno et al. [4544] where response for 388 
electrochemotherapy performed under general versus local anaesthesia was compared and 389 
found a significant increase in CR% for patients who underwent general anaesthesia. In 390 
addition, in the study by Bertino et al. [9] the response of tumours that were treatment-naïve 391 
was compared with tumours that had been previously treated with surgical-excision or 392 
irradiation. The authors found the treatment-naïve tumours responded significantly better 393 
than the previously treated tumours. These additional analyses further enrich the breadth of 394 
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knowledge about the usefulness of electrochemotherapy and provide valuable information for 395 
the review question and implications for future research. 396 
 397 
4.2 Limitations 398 
Overall, the methodological quality of the included studies was acceptable. Baseline 399 
characteristics were reported in the majority of studies, the outcome measure was fairly 400 
consistent across the included studies. However, there was inconsistency across the studies in 401 
the timing of the tumour evaluation with a range of 30 days – three months, with three studies 402 
not reporting the time period to tumour evaluation [3029-3231]. This makes it very difficult 403 
to form any robust conclusions about their data. It is difficult to judge how much of an effect 404 
the difference in time to evaluation had on the reliability of the results, but it is noteworthy 405 
that the Standard Operating Procedures recommended a period of four weeks before 406 
treatment efficacy of electrochemotherapy can be determined.  407 
The survival analysis was poorly reported and inconsistent across the studies which is 408 
unfortunate as these data are of great interest to clinicians particularly when deciding whether 409 
a treatment is worthwhile in the context of palliative care. The data extracted from the studies 410 
do give an indication of the medium length of follow-up in each individual study and 411 
percentage of patients whose disease was kept at bay. It is therefore useful information to 412 
display regardless of the fact that it is not possible to obtain an overall pooled average 413 
survival statistic. 414 
Another limitation of the included studies was the use of co-interventions. These are 415 
significant as they illustrate that there are fundamental differences in the experience of a 416 
portion of patients within the studies due to adjunct treatments which may affect the tumour 417 
response data. It may also be this was more widespread than can be identified in the full-text 418 
articles if some articles did not publish the additional interventions the patients underwent in 419 
their studies. However, it can be argued that due to the disease severity of the patients in 420 
these studies it would be considered unethical to deny them the opportunity to be exposed to 421 
other tumour-targeting therapies that may assist them to alleviate the burden of living with 422 
metastatic cutaneous tumours.     423 
Overall, this systematic review includes a representative sample of the available literature on 424 
this topic area for meaningful conclusions to be made. The study selection, data extraction 425 
and study appraisal aspects of this review were carried out appropriately however, they would 426 
have been much more robust if there had been a second reviewer. Due to the availability of 427 
studies with large sample sizes, studies with less than ten participants were excluded to 428 
purposely limit the number of studies for analysis. However, the fact this occurred meant 429 
some very pertinent articles were removed that would have increased the knowledge to 430 
answer the review question [4645-4847]. 431 
 432 
The methods of statistical analysis were appropriate and valid in this review and an academic 433 
statistician was consulted for guidance on conducting the meta-analysis. Unfortunately, there 434 
was poor precision due to the fact there were only five studies eligible for the analysis, and it 435 
may therefore be misleading to draw firm conclusions from the summary effect.  436 
 437 
4.4 Conclusions 438 
This aim of this systematic review was to consolidate the recent literature on the effectiveness 439 
of electrochemotherapy for cutaneous metastases and update the previous systematic reviews 440 
[1, 2]. It was evident during the review process that the period of four weeks recommended 441 
by the Standard Operating Procedures as the time to measure tumour response to 442 
electrochemotherapy may not be long enough for large tumours to respond. In the study by 443 
Matthiessen et al. [2625] the patients all had large tumours from breast cancer and used an 444 
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eight week follow up instead of the four weeks to allow for this. Another factor noted in this 445 
review is that larger tumours may benefit from using different plates and electrodes. 446 
Additionally, a higher concentration of drug in large tumours could be achieved by 447 
combining both intratumoural and systematic administration of chemotherapy. This review 448 
used meta-analysis to show that small tumours have a greater tumour response compared to 449 
large tumours, further meta-analyses comparing other sub-groups would be useful in future 450 
reviews such as whether previous irradiation and number of tumours per patient influences 451 
the effectiveness of electrochemotherapy. Matching the treatment modality and schedule to 452 
patient specific factors such as those identified above is crucial to ensure the most effective 453 
coverage of the tumour by the electric field which means treatment needs to become more 454 
tailored to the individual. 455 
Another implication for future treatment is that many of the studies reported some 456 
participants were able to obtain and/or maintain tumour response by undergoing repeated 457 
sessions of electrochemotherapy. Unfortunately, there was a lack of data providing the 458 
tumour responses to the additional cycles of electrochemotherapy. Further research should 459 
aim to explore this to set standards for the frequency of electrochemotherapy sessions to 460 
provide the highest benefit and lowest possible harm to patients. This could be done by better 461 
reporting of the number of cycles and results of the retreatments. Another issue this review 462 
has exposed is the lack of consistency in reporting of survival statistics as well as secondary 463 
outcomes such as QOL, pain and toxicity. Future research should address these outcomes as 464 
they inform health resource use and patient preference especially in palliative care. 465 
This systematic review shows electrochemotherapy is an effective palliative treatment with 466 
minimal adverse reactions. Moreover, it should be considered early in the development of 467 
cutaneous metastases as the smaller the tumour the more effective the treatment. Larger 468 
tumours will need to have tailored approaches to maximise the effectiveness of the ECT 469 
treatment, such as using different plates and electrodes.  470 
The evidence included in this review wasis based on the studies conducted following 471 
publication of the standard operating procedures in 2006 [8], it is noted that there has been an 472 
updated version of these standard operating procedures published in 2018 [10]. This update 473 
reflects the considerable experience gained in the use of the treatment in a wide range of 474 
tumour histologies. Future studies going forward, which use the updated standards may 475 
generate morefurther clinically specific evidence to guide clinicians. The knowledge 476 
generated by this review can provideprovides further validationevidence generated from 477 
clinical studies, which followed the 2006 for inform publications such as the Standard 478 
Operating Procedures [8, 10] and inform clinical practice guidelines such as the NICE 479 
guidelines [1211] to ensure they are brought up-to-date with current evidence.  480 
Acknowledgements 481 
The first author of this paper is Josephine Morley who conducted the systematic review and 482 
meta-analysis and was supervised by Professor Patricia Grocott and Trevor Murrells at 483 
King’s College London. Statistical support was provided by Dr Edward Purssell Senior 484 
Lecturer at City, University of London. This paper has not been submitted for publication 485 
elsewhere.  486 
Funding  487 
The Author(s) received no financial support for the research, authorship, and/ or publication 488 
of this article. 489 
Declaration of conflicts of interest 490 
The author(s) declare(s) that there is no conflict of interest.  491 
Ethics/research governance approvals 492 
This is a systematic review of primary studies. Obtaining ethical approval was not applicable. 493 
21 
 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
References  503 
[1] Mali B, Jarm T, Snoj M, et al. Antitumor effectiveness of electrochemotherapy: a 504 
systematic review and meta-analysis. Eur J Surg Oncol 2013; 39(1):4-16. 505 
[2] Mali B, Miklavcic D, Campana LG, et al. Tumor size and effectiveness of 506 
electrochemotherapy. Radiology and oncology 2013;47(1):32-41. 507 
[3] Schwartz RA. Cutaneous metastatic disease. J Am Acad Dermatol 1995;33(2):161-185. 508 
[4] Alexander S. Malignant fungating wounds: epidemiology, aetiology, presentation and 509 
assessment. J Wound Care 2009;18(7):273-280. 510 
[5] Grocott P, Gethin G, Probst S. Malignant wound management in advanced illness: new 511 
insights. Current opinion in supportive and palliative care 2013;7(1):101-105. 512 
[6] Spratt DE, Gordon Spratt EA, Wu S, et al. Efficacy of skin-directed therapy for cutaneous 513 
metastases from advanced cancer: a meta-analysis. J Clin Oncol 2014;32(28):3144-3155. 514 
[7] Miklavcic D, Corovic S, Pucihar G, et al. Importance of tumour coverage by sufficiently 515 
high local electric field for effective electrochemotherapy. European Journal of Cancer 516 
Supplements 2006;4(11):45-51. 517 
[8]  Marty M, Sersa G, Garbay JR, et al. Electrochemotherapy–An easy, highly effective and 518 
safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European 519 
Standard Operating Procedures of Electrochemotherapy) study. European Journal of Cancer 520 
Supplements 2006;4(11):3-13. 521 
[9] Bertino G, Sersa G, De Terlizzi F, et al. European Research on Electrochemotherapy in 522 
Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. Eur J 523 
Cancer 2016;63:41-52. 524 
[10] Gehl et al. Updated standard operating procedures for electrochemotherapy of cutaneous 525 
tumors and skin metastases. Acta Oncol. 2018;57(7):874-882 526 
[1110] Matthiessen LW, Chalmers RL, Sainsbury DCG, et al. Management of cutaneous 527 
metastases using electrochemotherapy. Acta Oncol 2011;50(5):621-629 528 
[1211] National Institute of Clinical Excellence, NICE. Electrochemotherapy for metastases 529 
in the skin from tumours of non-skin origin and melanoma. 2013; Available at: 530 
https://www.nice.org.uk/guidance/ipg446. Accessed 07/03, 2018. 531 
[1312] Moher D, Liberati A, Tetzlaff J, et al. Prisma Group. Preferred reporting items for 532 
systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 533 
2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097 (accessed on 07/03, 534 
2018) 535 
[1413] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response 536 
to treatment in solid tumors. J Natl Cancer Inst 2000;92(3):205-216. 537 
[1514] Boland A, Cherry MG, Dickson R. Doing a systematic review a students guide. 538 
London: SAGE Publication Ltd; 2014. 539 
[1615] Sibbald B, Roland M. Understanding controlled trials. Why are randomised controlled 540 
trials important? BMJ 1998;316(7126):201. 541 
Formatted: Font: (Default) Times
New Roman
23 
 
[1716] Moga C, Guo B, Schopflocher D, et al. Development of a Quality Appraisal Tool for 542 
Case Series Studies Using a Modified Delphi Technique. 2012; Available at: 543 
https://www.researchgate.net/publication/281411226_Development_of_a_Quality_Appraisal544 
_Tool_for_Case_Series_Studies_Using_a_Modified_Delphi_Technique. (accessed on 07/03, 545 
2018) 546 
[1817] Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools for 547 
preclinical and clinical studies, systematic review and meta‐ analysis, and clinical practice 548 
guideline: a systematic review. Journal of evidence-based medicine 2015;8(1):2-10. 549 
[1918] Borenstein M, Hedges L, Higgins J.et al. Introduction to meta-analysis. West Sussex, 550 
England: Wiley & Sons Ltd 2009. 551 
[2019] Ried K. Interpreting and understanding meta-analysis graphs: a practical guide. 552 
Australian Family Physician, 2006; 35(8):635-638 553 
[2120] Del Re A. A practical tutorial on conducting meta-analysis in R. The Quantitative 554 
Methods for Psychology 2015;11(1):37-50. 555 
[2221] Sutton AJ. Evidence concerning the consequences of publication and related biases. 556 
Publication bias in meta-analysis: Prevention, assessment, and adjustments. John Wiley & 557 
Sons, Ltd, 2005:175-192. 558 
[2322] Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. : 559 
John Wiley & Sons; 2011. 560 
[2423] Cabula C, Campana LG, Grilz G, et al. Electrochemotherapy in the Treatment of 561 
Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis. Annals of 562 
Surgical Oncology 2015;22:442-450. 563 
[2524] Di Monta G, Caraco C, Simeone E, et al. Electrochemotherapy efficacy evaluation for 564 
treatment of locally advanced stage III cutaneous squamous cell carcinoma: A 22-cases 565 
retrospective analysis. Journal of Translational Medicine 2017;15: 82 566 
[2625] Matthiessen LW, Johannesen HH, Hendel HW, et al. Electrochemotherapy for large 567 
cutaneous recurrence of breast cancer: a phase II clinical trial. Acta Oncol 2012;51(6):713-568 
721. 569 
[2726] Benevento R, Santoriello A, Perna G, et al. Electrochemotherapy of cutaneous 570 
metastasis from breast cancer in elderly patients: a preliminary report. BMC surgery 571 
2012;12(1):S6. 572 
[2827] Ricotti F, Giuliodori K, Cataldi I, et al. Electrochemotherapy: an effective local 573 
treatment of cutaneous and subcutaneous melanoma metastases. Dermatologic Therapy 574 
2014;27(3):148-152. 575 
[2928] Miller A, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. 576 
Cancer 1981;47(1):207-214. 577 
[3029] Campana LG, Mali B, Sersa G, et al. Electrochemotherapy in non-melanoma head and 578 
neck cancers: a retrospective analysis of the treated cases. Br J Oral Maxillofac Surg 579 
2014;52(10):957-964. 580 
[3130] Kreuter A, van Eijk T, Lehmann P, et al. Electrochemotherapy in advanced skin 581 
tumors and cutaneous metastases - a retrospective multicenter analysis. Journal der 582 
Deutschen Dermatologischen Gesellschaft 2015;13(4):308-315. 583 
[3231] Tomassini GM, Covarelli P, Tomassini MA, et al. Electrochemotherapy with 584 
intravenous bleomycin for advanced non-melanoma skin cancers and for cutaneous and 585 
subcutaneous metastases from melanoma. Giornale Italiano di Dermatologia e Venereologia 586 
2016;151(5):499-506. 587 
[3332] Euser AM, Zoccali C, Jager KJ, et al. Cohort studies: prospective versus retrospective. 588 
Nephron Clin Pract 2009;113(3):c214-7. 589 
[3433] Vandenbroucke JP. Prospective or retrospective: what's in a name? BMJ 590 
1991;302(6771):249-250. 591 
25 
 
[3534] Campana LG, Marconato R, Valpione S, et al. Basal cell carcinoma: 10-year 592 
experience with electrochemotherapy. Journal of Translational Medicine 2017;15:122. 593 
[3635] Kunte C, Letule V, Gehl, et al. Electrochemotherapy in the treatment of metastatic 594 
malignant melanoma: a prospective cohort study by InspECT. Br J Dermatol 595 
2017;176(6):1475-1485. 596 
[3736] Di Monta G, Caraco C, Benedetto L, et al. Electrochemotherapy as "new standard of 597 
care" treatment for cutaneous Kaposi's sarcoma. European Journal of Surgical Oncology 598 
2014;40(1):61-66. 599 
[3837] Curatolo P, Quaglino P, Marenco F, et al. Electrochemotherapy in the treatment of 600 
Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Annals of Surgical 601 
Oncology 2012;19(1):192-198. 602 
[3938] Campana LG, Valpione S, Mocellin S, et al. Electrochemotherapy for disseminated 603 
superficial metastases from malignant melanoma. Br J Surg 2012;99(6):821-830. 604 
[4039] Campana LG, Testori A, Curatolo P, et al. Treatment efficacy with 605 
electrochemotherapy: A multi-institutional prospective observational study on 376 patients 606 
with superficial tumors. European Journal of Surgical Oncology 2016;42(12):1914-1923. 607 
[4140] Mir LM. Bases and rationale of the electrochemotherapy. European Journal of Cancer 608 
Supplements 2006;4(11):38-44. 609 
[4241] Campana LG, Mocellin S, Basso M, et al. Bleomycin-based electrochemotherapy: 610 
clinical outcome from a single institution's experience with 52 patients. Annals of Surgical 611 
Oncology 2009;16(1):191-199. 612 
[4342] Quaglino P, Mortera C, Osella-Abate S, et al. Electrochemotherapy with intravenous 613 
bleomycin in the local treatment of skin melanoma metastases. Annals of Surgical Oncology 614 
2008;15(8):2215-2222. 615 
[4443] Sersa G, Jarm T, Kotnik T, et al. Vascular disrupting action of electroporation and 616 
electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 2008;98(2):388. 617 
[4544] Rotunno R, Marenco F, Ribero S, et al. Electrochemotherapy in non-melanoma head 618 
and neck skin cancers: A three-center experience and review of the literature. Giornale 619 
Italiano di Dermatologia e Venereologia 2016;151(6):610-618. 620 
[4645] Kis E, Oláh J, Ócsai H, et al. Electrochemotherapy of cutaneous metastases of 621 
melanoma—a case series study and systematic review of the evidence. Dermatologic Surgery 622 
2011;37(6):816-824. 623 
[4746] Kis E, Szegesdi I, Ócsai H, et al. Electrochemotherapy of melanoma cutaneous 624 
metastases. Orv Hetil 2010;151(3):99-101. 625 
[4847] Seccia V, Muscatello L, Dallan I, et al. Electrochemotherapy and its controversial 626 
results in patients with head and neck cancer. Anticancer Res 2014;34(2):967-972. 627 
[4948] Campana LG, Valpione S, Falci C, et al. The activity and safety of 628 
electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: 629 
a phase-II study. Breast Cancer Research & Treatment 2012;134(3):1169-1178. 630 
[5048] Caraco C, Marone U, Simeone E, et al. Electrochemotherapy in melanoma patients: A 631 
single institution experience. Melanoma Management 2015;2(2):127-132. 632 
[5149] Caraco C, Mozzillo N, Marone U, et al. Long-lasting response to electrochemotherapy 633 
in melanoma patients with cutaneous metastasis. BMC Cancer 2013;13:564. 634 
[5250] Gargiulo M, Papa A, Capasso P, et al. Electrochemotherapy for non-melanoma head 635 
and neck cancers: clinical outcomes in 25 patients. Ann Surg 2012;255(6):1158-1164. 636 
[5351] Guida M, Campana LG, Curatolo P, et al. Local treatment with electrochemotherapy 637 
of superficial angiosarcomas: Efficacy and safety results from a multi-institutional 638 
retrospective study. J Surg Oncol 2016;114(2):246-253. 639 
27 
 
[5452] Latini A, Bonadies A, Trento E, et al. Effective treatment of Kaposi’s sarcoma by 640 
electrochemotherapy and intravenous bleomycin administration. Dermatologic Therapy 641 
2012;25(2):214-218 642 
[5553] Mevio N, Bertino G, Occhini A, et al. Electrochemotherapy for the treatment of 643 
recurrent head and neck cancers: preliminary results. Tumori 2012;98(3):308-313. 644 
[5654] Mir-Bonafe JM, Vilalta A, Alarcon I, et al. Electrochemotherapy in the treatment of 645 
melanoma skin metastases: a report on 31 cases. Actas Dermo-Sifiliogr 2015;106(4):285-291. 646 
[5755] Skarlatos I, Kyrgias G, Mosa E, et al. Electrochemotherapy in cancer patients: first 647 
clinical trial in Greece. In Vivo 2011;25(2):265-274. 648 
[5856] Solari N, Spagnolo F, Ponte E, et al. Electrochemotherapy for the management of 649 
cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent. J 650 
Surg Oncol 2014;109(3):270-274. 651 
 652 
 653 
 654 
 
 
 Original Data Data used in evaluation Eligibility for  
meta-analysis 
First author, 
year 
published 
Study type Included 
no. of 
evaluable 
patients/ 
tumours 
Response of skin cancer (%) response 
evaluation 
time 
Drug/route Type of 
tumour(s) 
Response 
evaluation 
 follow- up  
median(range) 
Tumour 
types 
Tumour 
size CR (%) PR (%) NR/SD 
(%) 
PD (%) NA 
(%) 
a
 Benevento 
et al.[27] 
Prospective, 
observational 
12/142 107(75.3)  24(17) 11(7.7) - - At least 
30 days 
Bleo i.v. breast RECIST 210days (30-
354) 
no no 
a
 Bertino et 
al.[9] 
Prospective, 
observational, 
longitudinal 
99/99 62(~62.6) 
 
19(~19.2) 
 
13(~13.1) 
 
4(~4)  1(~1)  2 months Bleo i.v or 
i.t. 
H&N 
(BCC,SCC,MM, 
others
c
) 
RECIST 
(1.1) 
6 months (15 
days- 12 
months) 
yes yes 
 a
 Cabula et 
al.[34] 
Retrospective  
cohort study 
113/214 66(58.4) 36(31.8) 8(7.1) 2(1.8) 1(0.9) 2 months Bleo i.v or 
i.t. 
breast RECIST 
(1.1) 
5.9 months (3-
58 months) 
no yes 
Campana et 
al.[35]  
Retrospective 
observational 
84/185 42(50) 30(36) 12(14) - - 1-2 month  Bleo i.v or 
i.t. 
BCC
d 
 RECIST 49.2 months 
(3.6 – 121.1) 
no yes 
Campana et 
al.[40] 
Prospective 
observational 
226/811 113(50) 75(33.2) 30(13.3) 7(3.1) 1(0.4) 60 days Bleo i.v or  
bleo/cisp 
i.t. 
Breast, BCC,SCC, 
KS, STS, 
melanoma, 
others
e
 
RECIST 13.9 
months(0.4-
63.2) 
yes yes 
Campana et 
al.[30] 
retrospective 39/- 15(38) 8(21) 15(38) 1(3) - - Bleo i.v or  
bleo/cisp 
i.t. 
Oral/oropharynx, 
non-melanoma 
RECIST 14 months (3-
82) 
no yes 
Campana et 
al.[49] 
Phase II trial 35/196 19(54.3) 13(37.1) 3(8.6) - - 2 months Bleo i.v. Chest wall  RECIST 32 months (6-
53) 
no no 
Campana et 
al.[39] 
observational 85/894 41(48) 39(46) 3(4) 2(2) 
patient 
- 1 month Bleo i.v or 
i.t. 
melanoma RECIST 26 (6-47) 
months 
no yes 
Campana et 
al.[42] 
Prospective, 
phase II 
52/608 26(50) 24(46) 2(4) - - 1 month Bleo i.v or 
i.t. 
Melanoma, 
breast, STS, SCC, 
H&N 
RECIST 9(2-21) 
months 
no yes 
b
Caraco et 
al.[50]
 
observational 89/- 43(48.3) 34(38.2) 12(13.5) - - 3 months Bleo i.v. Metastatic 
melanoma 
WHO 27.5(6-67) 
months 
no no 
b
Caraco et 
al.[51]
 
observational 60/- 29(48.4) 23(38.3) 8(13.3) - - 3 months Bleo i.v. Metastatic 
melanoma 
WHO 27.5(6-67) 
months 
no no 
Curatolo et 
al.[38] 
Prospective, 
phase II 
23/- 14(60.9) 9(39.1) - - - 4 weeks Bleo i.v. KS RECIST 7 
tumours 
1.5 years (2 
months-4.2 
yrs) 
no yes 
Di Monta. 
et al.[25] 
retrospective 22/- 5(22.7) 13(59) 3(13.6) 1(4.5) - 4 weeks Bleo i.v. Locally advanced 
SCC 
RECIST 34(5-48) 
months 
No no 
Di Monta et 
al.[37]  
prospective 19/- 14(73.6) - - - - 4 weeks Bleo i.v. KS RECIST 16(6-31) 
months 
13 (3-28) 
months 
- - 
Table 1 +  2
 
 
Gargiulo et 
al.[52] 
retrospective 25/- 18(72) 7(28) - - - 6 weeks Bleo i.v. H&N: SCC, BCC, 
adenocarcinoma  
WHO, 
biopsy 
21.9(4-42) 
months 
no yes 
Guida et 
al.[53] 
retrospective 19/54 8(42) 4(21) 6(32) 1(5) - 2 months Bleo i.v. angiosarcomas RECIST 7 
tumours 
12(4.7-12.8) 
months 
no no 
Kreuter et 
al.[31] 
retrospective 56/ 6(10.7) 19(33.9) 7(12.5) 24(42.9) - - Bleo i.v. Melanoma, BC, 
carcinoma, 
sarcoma 
RECIST  yes no 
Kunte C. et 
al.[36] 
prospective 114/394 55(48) 29(25) 26(23) 3(3) 1(1) 60 days Bleo i.v or 
i.t. 
Metastatic 
melanoma 
RECIST 116(66-201) 
days 
no yes 
Latini et 
al.[54] 
prospective 18/- 16(89) 2(11) - - - 4 weeks Bleo i.v. KS WHO (6 – 48 
months) 
no no 
a
Mevio et 
al.[55]
 
prospective 14/31 19(61.5)
g
 10(32.5)
g 
1(3)
g
 1(3)
g
  8 weeks Bleo i.v. H&N RECIST 8.75(2-
20)months 
- - 
Mir-Bonafe 
et al.[56] 
retrospective 31/- 7(23) 15(49) - 9(28)  1 month Bleo i.v. Melanoma  Own 
measures 
1 year (no 
median) 
- - 
Quaglino et 
al.[43] 
prospective 14/233 7 6 1 - - 8 weeks Bleo i.v. Melanoma  WHO 4-7 
tumours 
21(5-28) 
months 
no yes 
Ricotti et 
al.[28]  
prospective 30/654 6(20) 24(80) - - - 4 weeks Bleo i.v. melanoma WHO 20 months (no 
median) 
no yes 
Rotunno et 
al.[45] 
prospective 55/- 33(60) 17(31) 4(7) 1(1.8)  8 weeks Bleo i.v. H&N RECIST, 
biopsy 
8 months 
(327) 
no no 
Skarlatos et 
al.[57] 
prospective 47/- 30(63.83) 15(31.91) 2(4.26) - - 2 months Bleo i.v or 
i.t. 
Melanoma, KS, 
H&N, BC, others
f
 
Own 
measures 
At least 6 
months 
yes no 
Solari et 
al.[58] 
prospective Total = 39: 
20/- 
melanoma 
 - Bleo i.v. Melanoma, BC, 
KS,BCC, SCC, MC, 
AS, AC 
RECIST At least 6 
months 
yes yes 
2(10) 9(45) 3(15) 6(30) - 
19/- other 7(36.8) 8(42.1) - 4(21.1) - 
a
 Tomassini 
et al.[32]
 
prospective Total= 
 -/16: 
 2 months Bleo i.v. MM, NMSC RECIST - yes no 
MM -/9 
‘target’ 
3(33.3) 0 4(44.4) 2(22.3) 0 
-/7 
NMSC 
‘target’ 
6(85.7) 0 1(14.3) 0 0 
Matthiessen 
et al.[26] 
Phase II 12/25 1 1 9 1 - 8 weeks Bleo i.v or 
i.t. 
BC RECIST, 
PET/CT  
79(11-378) 
days 
no no 
 
 
 
 
 
 
Table 1. Summary of studies and characteristics of tumours included in the systematic review 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 
Matthiessen 
et al.[11] 
 
Phase II 24/97 58(60) 18(10) 11(11) 7(7) 3(3) >60 days Bleo i.v or 
i.t. 
BC RECIST 47(16-110) 
days 
no yes 
Key 
 
a) Number of responses per tumour reported 
b) Caraco et al.
 
[48] is an update of Caraco et al.[49] with an increased data set of patients 
c) 3 undifferentiated carcinoma, 3 adenocarcinoma, 1 lentigo maligna, 1 syringoma, 1 sarcomatous tumour 
d) BCC local 40(48%), locally advanced 41 (49%) and metastatic 3(3%) 
e) Merkel cell carcinoma, vulvar carcinoma, H&N 
f) Solid tumours including liposarcoma, anal, vulvar, uterine cervix, renal, pancreatic 
CR = complete response; PR = partial response; NR = no response; - = no data; bleo = bleomycin; cisp = cisplatin; i.t. = intratumoural; i.v. = intraveonou; BC = breast cancer; BCC = basal cell carcinoma; SCC = 
squamous cell carcinoma; H&S = Head and neck; KS = Kaposi sarcoma; STS = soft tissue sarcoma; AS = angiosarcoma; MC = merkel cell; AC = adenocarcinoma; MM= melanoma metastases; NMSC= non 
melanoma skin cancer 
 
 
 
Table 2. Summary of the studies including number of ECT cycles and secondary outcomes reported 
 
First author, year 
published 
Maximum 
number of 
ECT cycles 
performed 
No. of 
patients 
that 
received 
2 + 
courses 
Response of skin cancer (%) for second 
cycle 
Secondary outcomes reported 
CR (%) PR (%) NR/SD 
(%) 
PD 
(%) 
NA 
(%) 
Quality of life/PROS 
(patient reported 
outcome measures) 
toxicity pain Progression 
free survival 
% (CI) 
Whole cohort 
Progression 
free survival 
% (CI) CR 
Local 
control rate 
(%) 
Benevento et al.[26]  3 4 - - - - - - - - - -  
Bertino et al.[9]  2 19 - - - - - yes - yes - 89(69-97) 1 
year 
 
Cabula et al.[23] - - - - - - - no yes yes 86.2(79.3-
93.8) 1 year 
96.4(91.6-
100) 
 
Campana et al.[34]  3 24 11(45.8) 11(45.8) 2(8.4) - - - yes yes 70(58-82) (5 
years) 
-  
Campana et al.[39] 6 89(23.7%) - - - - - yes yes - 73.7(68.4-
37.6) one year 
-  
Campana et al.[29]  3 15(38) - - - - - no yes no    
Campana et al.[48] 3 21(59.7) - - - - - - yes yes   81% 3 
year 
Campana et al.[38] 6 61 30 31 - - - no yes no 87% (2 
year) 
  
Campana et al.[41]  5 20 13(65) 7(35)  - - - yes yes yes - - 96% 9(2-
21) months 
Caraco C. et al.[48]  6 50 - - - - - no no no - - - 
Caraco et al.[49] 5 26 - - - - - no no no - - - 
Curatolo et al.[37] 3 5 - - - - - no no no - - 76.2% (2 
years) 
Di Monta et al.[24] - - - - - - - no no no - - - 
Di Monta et al.[36]  3 5 - - - - - no no no - - - 
Gargiulo et al.[50] 2 4 - - - - - no yes no - - - 
Guida et al.[51] 3 4 - - - - - no yes yes 45%(12-69) - - 
Kreuter et al.[30] - - - - - - - no no no - - - 
Kunte C. et al.[35] 4 31 - - - - - no yes yes 74(64-68) 1 
year LPFS 
- - 
Latini et al.[52] 3 9 8(89) 1(11) - - - - - - - - - 
Mevio et al.[53] 3 - - - - - - - - - - - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mir-Bonafe et al.[54]  3 24 - - - - - - - - - - - 
Quaglino et al.[42] 3 10 - - - - - no no no - - 74.5%(2 
years) 
Ricotti et al.[27]  2 25 - - - - - no no no - - 72%(24 
month) 
Rotunno et al.[44]  3 23 - - - - - yes yes yes - - - 
Skarlatos et al.[55] 3 18 - - - - - no no no - - - 
Solari et al.[56] 4 17 - - - - - - - - - - - 
Tomassini et al.[31]  2 4 - - - - - - - - - - - 
Matthiessen et 
al.[25] 
4 7 - - - - - yes yes no - - - 
Matthiessen et 
al.[10] 
2 11 - - - - - no yes no - - - 
  
 Table 1. Data for small and large tumours included in meta-analysis
Author, 
year of 
publication 
Tumour  
sizes 
Number 
of 
tumours 
(small)= 
n1 
Complete response 
of tumours (small) 
number (%) 
 
Number of 
tumours 
(large) = 
n2 
Complete 
response of 
tumours 
(large) 
number (%) 
Bertino et 
al. 2016
9
 
≤ 3 cm 
  3cm 
68  53(78) 31  9(29) 
Cabula et 
al. 2015
24
 
< 3 cm 
  3cm 
55 44(80.3) 58 27(46.1) 
Campana et 
al. 2017
35
 
≤ 3 cm 
  3cm 
52 36(69.2) 
 
32 6(18.7) 
Kunte et al. 
2016
36
 
≤ 3 cm 
  3cm 
343 216(62.9) 51 18(35.3) 
Wichmann 
Matthiesse
n et al. 
2011
11
 
≤ 3 cm 
  3cm 
84 57(68) 
 
13 1(8) 
Table 3
 
Study reference Question no. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Score 
n/18 
Benevento et al.[27] Y Y N Y U Y U Y P  Y U Y N y Y N Y Y Y P 11.5 
Bertino et al.[9] Y Y Y Y Y Y Y Y P Y U Y N Y Y Y Y Y Y Y 17 
Cabula et al.[24] Y N Y U Y Y Y Y N Y U Y N Y Y Y Y Y Y Y 15 
Campana et al.[35] Y N N Y Y Y Y Y Y 
 
Y U Y  N Y Y N Y Y Y Y 15 
Campana et al.[40] Y Y Y Y Y Y Y Y P Y U Y N Y Y Y Y Y Y Y 17 
Campana et al.[30] Y N Y U Y N Y Y P Y U Y N Y U Y Y Y Y Y 13 
Campana et al.[49] Y Y N U Y Y Y Y P Y U Y N Y Y N Y Y Y Y 14 
Campana et al.[39] Y Y Y U Y Y Y Y P Y U Y N Y Y Y Y Y Y Y 16 
Campana et al.[42] Y Y U Y Y Y Y Y Y Y U Y N Y Y Y Y Y Y N 16 
Caraco et al.[50]  Y U N U Y N Y Y P Y U Y N y Y Y Y Y Y Y 12.5 
Caraco et al.[51] Y U U U Y N Y Y P Y U Y N y Y Y Y Y Y Y 12.5 
Curatolo et al.[38] Y Y Y U Y Y Y Y P Y U Y N Y Y Y Y Y Y N 15 
Di Monta et al.[25] Y N N Y Y Y Y Y P Y U Y N Y Y Y Y Y Y Y 15 
Di Monta et al.[37] Y Y N Y Y N Y Y P Y U Y N y Y Y Y Y Y Y 15.5 
Gargiulo et al.[52] Y N N U Y Y Y Y P Y U Y N Y Y Y Y Y Y Y 14 
Guida et al.[53] Y N Y U Y N Y Y P Y U Y N Y Y N Y Y Y Y 13 
Kreuter et al.[31] Y N Y U Y N Y Y P Y U Y N Y U N N Y Y P 10 
Kunte et al.[36]  Y Y Y Y Y Y Y Y P Y U Y N Y Y Y Y Y Y Y 17 
Latini et al.[54] Y Y N U Y N Y Y P Y U N N y Y Y Y N Y N 11.5 
Mevio et al.[55] Y U N U Y Y Y Y P Y U Y N y Y Y Y Y Y Y 12.5 
Mir-Bonafe et al.[56] Y N N U Y P Y Y P Y U Y N y Y Y N Y Y Y 11.5 
Quaglino et al.[43] Y Y U Y Y Y Y Y P Y U Y N Y Y Y Y Y Y P 14 
Ricotti et al.[28] Y Y N Y N N Y Y P Y U Y N y Y Y Y Y Y N 12.5 
Rotunno et al.[45] Y Y Y U Y Y Y Y P Y U Y N Y Y Y Y Y Y N 15 
Skarlatos et al.[57] Y Y Y Y Y Y Y Y P Y U Y N y Y Y N Y Y N 14.5 
Solari et al.[58] Y Y N U Y Y Y Y p Y U Y N Y U Y Y Y Y P 13 
   
Tomassini et al.[32] Y Y N U Y Y Y Y P Y U Y N Y Y Y N Y Y N 13 
   
Table 4
Key: Y = yes, y = yes but less advanced, N = no, U = unclear, P = partial 
Table 4. Quality Appraisal Tool Scores 
Matthiessen et al.[26] Y Y U U Y Y Y Y P Y U Y N y Y Y Y Y Y Y 14.5 
Matthiessen et al.[11]  Y Y Y Y Y Y Y Y P Y U Y N y Y Y Y Y Y Y 16.5 
Figure 1. Selection process for the studies included in the systematic review 
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